Search

Your search keyword '"Simplified Disease Activity Index"' showing total 127 results

Search Constraints

Start Over You searched for: Descriptor "Simplified Disease Activity Index" Remove constraint Descriptor: "Simplified Disease Activity Index"
127 results on '"Simplified Disease Activity Index"'

Search Results

51. Common Evaluations of Disease Activity in Rheumatoid Arthritis Reach Discordant Classifications across Different Populations

52. Consideration of differences in drug usage between young-onset and elderly-onset rheumatoid arthritis with target of low disease activity.

53. Reliability of patient-reported outcomes in rheumatoid arthritis patients: an observational prospective study

54. Sex Differences in the Effects of a Biological Drug for Rheumatoid Arthritis on Depressive State

55. Efficacy of tocilizumab on MRI-determined bone oedema in rheumatoid arthritis

56. A PREDICTIVE MODEL FOR SIMPLIFIED DISEASE ACTIVITY INDEX (SDAI) REMISSION IN RHEUMATOID ARTHRITIS

57. Normal serum matrix metalloproteinase-3 levels can be used to predict clinical remission and normal physical function in patients with rheumatoid arthritis

58. FRI0187 Radiographic progression by disease activity states in patients with rheumatoid arthritis treated with sb2 or reference infliximab

59. SAT0061 Haq score is an independent predictor of sustained remission in patients with rheumatoid arthritis

60. THU0070 Treat-to-target in ra: what level of treatment response is necessary by 3 months in order to achieve the treatment target by 6 months? results from a real life study

61. SAT0126 Mental health benefits associated with reduction in disease activity among rheumatoid arthritis patients: a systematic review of the literature

62. Predictor of the Simplified Disease Activity Index 50 (SDAI 50) at Month 3 of bDMARD Treatment in Patients with Long-Established Rheumatoid Arthritis

63. Measuring Disease Exacerbation and Flares in Rheumatoid Arthritis: Comparison of Commonly Used Disease Activity Indices and Individual Measures

64. Tight control of rheumatoid arthritis in a resource-constrained setting: a randomized controlled study comparing the clinical disease activity index and simplified disease activity index

65. Achieving simplified disease activity index remission in patients with active rheumatoid arthritis is associated with subsequent good functional and structural outcomes in a real-world clinical setting under a treat-to-target strategy

66. Comparative validation of clinical disease activity index (CDAI) and simplified disease activity index (SDAI) in rheumatoid arthritis in India

67. American College of Rheumatology/European League Against Rheumatism Remission Criteria for Rheumatoid Arthritis Maintain Reliable Performance When Evaluated in 44 Joints

68. After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?: Table 1

69. Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score With 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Cl

70. Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study

71. Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study

72. Simplified Disease Activity Index as an index of disease activity in patients with rheumatoid arthritis: a comparison with DAS28

73. How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?

74. Evaluation of changes in magnetic resonance images following 24 and 52 weeks of treatment of rheumatoid arthritis with infliximab, tocilizumab, or abatacept

75. Predictive Factors Related to the Efficacy of Golimumab in Patients with Rheumatoid Arthritis

76. Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components

77. Patient-reported Remission in Rheumatoid Arthritis

78. Validity and responsiveness of a self-administered foot evaluation questionnaire in rheumatoid arthritis

79. DAS28, CDAI and SDAI cut-offs do not translate the same information: results from the Rheumatic Diseases Portuguese Register Reuma.pt

80. Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia(®) as Biological Intensive Treatment for RA (ORBIT) study

81. Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy

82. Measuring flares in rheumatoid arthritis. (Why) do we need validated criteria?

83. The new ACR/EULAR remission criteria: rationale for developing new criteria for remission

84. THU0193 Response To Baricitinib at 4 Weeks Predicts Response at 12 and 24 Weeks in Patients with Rheumatoid Arthritis: Results from Two Phase 3 Studies: Table 1

85. FRI0191 Biosimilar Candidate ABP 501: Additional Efficacy Analyses from The Phase 3 Study: Table 1

86. FRI0582 Fluctuating Levels of Rheumatoid Factor Predict Progression of Rheumatoid Arthritis, but Not Independent of Disease Activity

87. Effect of rheumatologist education on systematic measurements and treatment decisions in rheumatoid arthritis: the metrix study

88. Comparison of Long-Term Clinical Outcome With Etanercept Treatment and Adalimumab Treatment of Rheumatoid Arthritis With Respect to Immunogenicity

89. The Simplified Disease Activity Index and Clinical Disease Activity Index to monitor patients in standard clinical care

90. The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care

91. THU0103 Differences in Patients with Rheumatoid Arthritis who Achieved DAS Remission or SDAI Remission but not Boolean Remission

92. AB0244 Correlation Between Serological and Clinical Markers in Rheumatoid Arthritis

93. SAT0053 The Added Value of Ultrasound to Evaluate Remission in Rheumatoid Arthritis: Table 1

94. AB0252 Comparison Between Clinical and Ultrasonographic Simplified Disease Activity Index in Rheumatoid Arthritis

95. THU0085 SDAI Remission at week 24 is a Predictor of Good Functional and Structural Outcomes at week 72 in a T2T Implementing Cohort

96. Origins of Discordant Responses among 3 Rheumatoid Arthritis Improvement Criteria.

97. The patient's perspective and rheumatoid arthritis disease activity indexes

98. FRI0033 Association of Radiographic Outcomes with Low Disease Activity and Remission and Sustainability of Response with Subcutaneous Abatacept or Adalimumab: 2-Year Results from the AMPLE Trial

99. SAT0246 Correlation of Clinical Response with Patient-Reported Outcomes in the AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve RA Patients with Background Methotrexate) Trial: 2-Year Results: Table 1

100. SAT0060 Best Chance of Achieving Remission in RA Patients with Very Short Disease Duration

Catalog

Books, media, physical & digital resources